cediranib cediranib cediranib (azd-2171; tentative trade name recentin) is a potent inhibitor of vascular endothelial growth factor (vegf) receptor tyrosine kinases. cediranibclinical dataroutes ofadministrationoralatc codel01ek02 (who) pharmacokinetic dataelimination half-life12 to 35 hoursidentifiers iupac name 4--6-methoxy-7-quinazoline cas number288383-20-0 ypubchem cid9933475iuphar/bps5664chemspider8109103 nuniinqu9ipy4k9keggd08881chemblchembl491473 ncomptox dashboard (epa)dtxsid10183035 echa infocard100.196.628 chemical and physical dataformulac25h27fn4o3molar mass450.514 g·mol−13d model (jsmol)interactive image smiles coc4cc3c(oc2ccc1c(c)cc1c2f)ncnc3cc4occcn5cccc5 inchi inchi=1s/c25h27fn4o3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29h,3-5,8-11h2,1-2h3 nkey:xxjwyddudkyvki-uhfffaoysa-n n ny (what is this?) (verify) the drug is being developed by astrazeneca as a possible anti-cancer chemotherapeutic agent for oral administration. clinical trials beginning in 2007, it underwent phase i clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children. phase i trials of interactions with other drugs used in cancer treatment were also undertaken. on february 27, 2008, astrazeneca announced that the use of cediranib in non-small cell lung cancer will not progress into phase iii after failing to meet its main goal. on 8 march 2010, astrazeneca issued a press-release stating that cediranib had failed phase iii clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader bevacizumab. in 2016, astrazeneca completed a phase iii trial comparing the efficacy of cediranib alone and cediranib with lomustine to the efficacy of lomustine alone in patients with recurrent glioblastoma. the trial failed to meet its primary endpoint and survival was not extended with cediranib. combination trials findings from a federally funded, nci-sponsored phase ii clinical trial presented at the 50th annual meeting of the american society of clinical oncology (may 30 - june 3, 2014, chicago, ill; abstract no: lba5500), show that the combination of two investigational oral drugs, olaparib, a parp inhibitor, and cediranib is significantly more active against recurrent, platinum chemotherapy-sensitive disease or ovarian cancer related to mutations in brca genes than olaparib alone.